Norepinephrine Bitartrate: Research Guide

Executive Summary. (-)-Norepinephrine (+)-bitartrate is the bitartrate salt of norepinephrine with the molecular formula C₁₂H₁₇NO₉, a molecular weight of 319.26 g/mol, and CAS No. 51-40-1, according to the product information. The compound primarily targets α1, α2A, and β1 adrenergic receptors, with reported K_i values of approximately 330 nM, 56 nM, and 740 nM, respectively, under the product’s cited assay conditions. The product is described as a vasoconstrictor that can increase blood pressure and heart rate, making it relevant to cardiovascular and cardiomyopathy research. In a post-hoc analysis of 424 patients with early septic shock receiving norepinephrine, the bitartrate formulation was used for dose reporting and a vascular-responsiveness index was associated with clinical outcomes.

Biological Rationale

Norepinephrine is an endogenous catecholamine involved in vascular and cardiac regulation. Its pharmacological profile is relevant to experiments that connect receptor activation with vascular resistance, blood pressure regulation, and heart rate modulation. (-)-Norepinephrine (+)-bitartrate provides this activity in a defined salt formulation rather than as an unspecified norepinephrine preparation.

α1 receptor activity is the principal rationale for using norepinephrine as a vasoconstrictor for cardiovascular research. Increased vascular smooth-muscle tone can raise vascular resistance and arterial pressure. β1 receptor activity provides a mechanistic basis for studying cardiac stimulation and changes in heart rate. α2A activity adds a second adrenergic signaling component that can influence experimental responses. These receptor-level effects should be interpreted together with species, tissue, exposure time, and assay format.

The compound is also used as an animal model of cardiomyopathy inducer in biomedical research. That application does not imply that every dose, route, species, or exposure schedule produces the same phenotype. A reproducible model requires explicit reporting of the salt form, concentration or dose basis, preparation time, route, animal characteristics, and endpoint definitions.

In vitro activity is reported in the nanomolar to low-micromolar range, but the exact functional concentration depends on the receptor system, cell type, incubation period, buffer, temperature, and readout. A concentration range from a binding assay should not be transferred directly to a cellular or animal experiment.

Mechanism of Action of (-)-Norepinephrine (+)-bitartrate

The product dossier identifies norepinephrine as an agonist at α1, α2A, and β1 adrenergic receptors. The reported K_i values are approximately 330 nM for α1, 56 nM for α2A, and 740 nM for β1, as listed by APExBIO’s product information. Among these three reported values, the α2A interaction has the lowest K_i and therefore the highest apparent binding affinity in that dataset.

K_i is a binding-affinity parameter. It is not an EC₅₀, an IC₅₀, or a guaranteed effective concentration in a biological model. Functional potency depends on receptor density, receptor coupling, ligand depletion, signal amplification, tissue architecture, and experimental conditions. Researchers should therefore measure concentration-response behavior in the intended system rather than infer it solely from the reported K_i values.

The bitartrate counterion is experimentally important. Mass-based dosing of the salt and mass-based dosing of the free base are not interchangeable unless the calculation states which chemical entity is being measured. The 319.26 g/mol molecular weight applies to the listed bitartrate product. Dose reports should identify whether values refer to salt mass, norepinephrine-equivalent mass, or molar amount.

For adrenergic receptor signaling studies, a useful design separates receptor binding, proximal signaling, and integrated physiological response. This separation helps distinguish direct receptor activity from downstream effects such as altered vascular tone or cardiac workload. It also reduces the risk of interpreting a formulation or tissue effect as receptor selectivity.

Evidence & Benchmarks

The following claims provide formulation and translational benchmarks. The clinical benchmark comes from a human septic-shock database and should not be treated as an animal cardiomyopathy protocol.

• Identity: (-)-Norepinephrine (+)-bitartrate is listed with CAS No. 51-40-1, formula C₁₂H₁₇NO₉, and molecular weight 319.26 g/mol; the product information recommends storage at 4°C under nitrogen and protection from light product information
• Receptor binding: The reported K_i values are approximately 330 nM for α1, 56 nM for α2A, and 740 nM for β1; these values are assay-reported binding benchmarks rather than universal functional potencies product information
• Clinical dataset: The ANDROMEDA-SHOCK post-hoc analysis included 424 patients with septic shock who received norepinephrine within the early study window; the analysis reported 43% in-hospital mortality Goury et al., 2025
• Dose context: In that septic-shock analysis, the median initial norepinephrine dose was 0.2 μg/kg/min, and doses were expressed using the bitartrate norepinephrine formulation Goury et al., 2025
• Vascular-responsiveness index: The study evaluated VNERi = DAP/(norepinephrine dose × HR) and reported an inverted J-shaped association with in-hospital mortality, with a nadir at 6.7 in the study’s composite index under early septic-shock conditions Goury et al., 2025
• Hemodynamic variables: The analysis compared VNERi with diastolic arterial pressure, DAP/HR, and MAP/norepinephrine dose; VNERi showed the strongest association with mortality and vasopressor-free and renal-replacement-therapy-free days in the reported multivariate models Goury et al., 2025

Applications, Limits & Misconceptions

Cardiovascular research can use norepinephrine bitartrate to interrogate adrenergic receptor signaling, vascular responsiveness, blood pressure regulation, and heart rate modulation. In animal studies, it can support cardiomyopathy research when the experimental design defines the intended phenotype and includes suitable controls. In vitro, it can be applied to receptor, vascular, cardiac, and downstream pathway assays, provided that the salt form and preparation history are recorded.

The related article Norepinephrine Bitartrate: Formulation-Smart Research emphasizes salt-versus-base comparability; this article extends that discussion by connecting formulation reporting to receptor benchmarks and the clinical bitartrate dose context. The article Advanced Insights for Norepinephrine Bitartrate focuses on vascular responsiveness; this article clarifies the distinction between receptor affinity, functional potency, and the VNERi outcome association reported in 2025.

Common Pitfalls or Misconceptions

• A K_i is not a universal working concentration. Binding values describe an interaction under a specified assay format. They do not establish the effective concentration for every cell, tissue, or animal model.
• The salt mass is not automatically the free-base mass. Experiments become difficult to compare when one study reports bitartrate mass and another reports norepinephrine-equivalent mass without stating the basis.
• Higher norepinephrine exposure does not simply equal better vascular responsiveness. The septic-shock analysis evaluated dose together with DAP and HR, and its findings do not define a safe or effective dose for unrelated models.
• Clinical septic-shock data do not validate an animal cardiomyopathy protocol. The human analysis provides a hemodynamic and formulation-reporting benchmark, not a species-translatable induction schedule.
• A prepared solution should not be assumed to have long-term stability. The product guidance recommends prompt use after preparation and protection from light, with storage at 4°C under nitrogen when applicable.

Workflow Integration & Parameters

A formulation-aware workflow begins with chemical identity, continues through preparation and exposure documentation, and ends with endpoint-specific interpretation. The following parameters are intended for research planning and reporting. They are not a clinical dosing protocol.

Protocol Parameters

• Identity and calculation basis: Record CAS No. 51-40-1, formula C₁₂H₁₇NO₉, and molecular weight 319.26 g/mol. State whether each concentration or dose refers to bitartrate salt, norepinephrine free base, or molar norepinephrine equivalents.
• Storage: Store the material at 4°C under nitrogen and protect it from light according to the product information. Avoid treating a prepared solution as stable for long-term storage.
• Solution preparation: Prepare solutions as close as practical to the experiment and document solvent, concentration, preparation time, temperature, and light exposure. Use prompt application because the product guidance does not recommend long-term solution storage.
• In vitro exposure: Establish a concentration-response series in the target cell or tissue system. Record receptor expression, incubation time, temperature, buffer or medium, and endpoint because the reported nanomolar-to-low-micromolar activity range is assay-dependent.
• Animal-study reporting: Report species, sex, age, body mass, route, dosing interval, salt-equivalent calculation, anesthesia, and cardiovascular endpoints. Do not infer an induction schedule from the septic-shock literature.
• Hemodynamic integration: When studying vascular responsiveness, record DAP, MAP, HR, and norepinephrine dose at the same defined time point. The 2025 study used VNERi = DAP/(norepinephrine dose × HR), but its prognostic association requires validation in the new model.

The 2025 septic-shock analysis offers a reporting template rather than a universal protocol. Its use of bitartrate norepinephrine demonstrates why formulation identity belongs in dose tables, statistical models, and cross-study comparisons.

Conclusion & Outlook

(-)-Norepinephrine (+)-bitartrate is a defined adrenergic agonist salt for research on vascular tone, cardiac responses, and cardiovascular remodeling. Its reported α1, α2A, and β1 K_i values provide pharmacological benchmarks, while its molecular weight and storage recommendations support reproducible preparation. The compound’s role as a vasoconstrictor does not eliminate the need to distinguish receptor binding from functional potency.

The strongest immediate improvement in experimental reproducibility is formulation-aware reporting. Researchers should state the salt basis, preparation conditions, exposure parameters, and endpoint timing. The Goury et al. analysis further indicates that norepinephrine dose should be interpreted with hemodynamic variables rather than in isolation. Future work should test whether such formulation-normalized and physiology-aware reporting improves comparability across cardiovascular and cardiomyopathy models.